The standard or original microcytotoxicity
assay (OMCA) has significant advantages over other
cytotoxicity assays, since it is able to detect both
cell necrosis and
apoptosis and it is simpler,
safer, more practical, and more economical. OMCA has serious weaknesses, however, such as low accuracy, low selectivity, and low sensitivity. These drawbacks are ameliorated or eliminated by pre-labeling of target
cell nuclei, for instance, with 5-bromo2′-
deoxyuridine. This improved microcytotoxicity
assay (IMCA) is readily adapted to a wide range of applications, such as screening of
cytotoxicity drug candidates, selecting an anticancer cytotoxic therapy, detecting abnormalities including reduced tumor
cell killing ability of NK cells in
cancer patients, predicting outcome of
cytokine therapy and
immunotherapy, determining effectiveness of
cytokine therapy and
immunotherapy in
follow up studies following treatment, determining effectiveness of anticancer cytotoxic therapy during and following therapy and ascertaining
cytotoxic T cell activity during anticancer
vaccination therapy.